ArticleBiomarker research2026
LACC1 attenuates LPS-induced acute lung injury by inhibiting inflammatory response in alveolar macrophage through LPAR3/PI3K/AKT/mTOR signaling pathway.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveLaccase domain containing 1 (LACC1) is an enzyme abundantly expressed in inflammatory macrophages that regulate diverse inflammatory diseases. This study aimed to investigate the role of LACC1 in lipopolysaccharide (LPS)-induced acute lung injury (ALI) and to elucidate its underlying regulatory mechanisms.
methodsSingle-cell RNA sequencing of bronchoalveolar lavage fluid (BALF) from patients with ALI was performed to characterize LACC1 expression patterns in pulmonary macrophages. Then, LACC1 conditional knockout mouse model was established to investigate the in vivo function of LACC1 during LPS-induced lung injury. ln vitro function of LACC1 was further explored using LACC1-silenced THP-1 cells. RNA sequencing was conducted to profile gene expression changes in LACC1-knockdown THP-1 cells, followed by GO and KEGG enrichment analysis. Key downstream molecules and signaling pathways modulated by LACC1 were validated by Western blot and qRT-PCR.
resultsSingle-cell RNA sequencing analysis based on BALF of ALI patients revealed that LACC1 expression was markedly elevated in pulmonary macrophages. Conditional knockout of LACC1 in macrophages exacerbated LPS-induced pulmonary inflammation. In vitro, LACC1 knockdown in THP-1 cells markedly exacerbated the inflammatory response after LPS treatment. RNA sequencing identified LPAR3 as a key downstream target, and enrichment analysis indicated significant involvement of phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway followed by LACC1 knockdown. Western blot analysis confirmed that LACC1 knockdown reduced LPAR3 expression and inhibited PI3K/AKT/mTOR pathway activation.
conclusionsLACC1 might exert a protective effect against LPS-induced lung injury by suppressing inflammatory responses via modulation of LPAR3/PI3K/AKT/mTOR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.